March 31st 2023
Data from the phase 3 TIGeR-PaC trial indicates that patients with locally advanced pancreatic cancer experienced notable survival benefit with RenovoGem vs chemotherapy.
January 21st 2023
Community Practice Connections™: Pathology Oncology Collaborative: Biomarker Testing in an Emerging Era of HER2 Across Breast, GI, and Lung Cancers
2nd Annual Virtual Tumor Board®: Integrating Emerging Testing Methodologies into Optimal Treatment Planning in Gastrointestinal Cancers
Community Practice Connections™: 19th Annual Meeting of the International Society of Gastrointestinal Oncology®
20th Annual Meeting of the International Society of Gastrointestinal Oncology®
Equalizing Inequities™ in Multiple Myeloma Care: Shining a Light on Current Barriers and Opportunities for Improved Outcomes
Clinical Vignettes: 40th Annual CFS®: Innovative Cancer Therapy for Tomorrow®
Community Practice Connections™: 6th Annual Precision Medicine Through Plasma™ – Using Liquid Biopsies in Contemporary Oncology Care
Medical Crossfire®: Antibody-Drug Conjugates Coming to Your Oncology Practice Tomorrow
Medical Crossfire®: Multidisciplinary Strategies to Leverage Clinical Advances on Immune-Based Therapies for Patients with Hepatocellular Carcinoma
8th Annual School of Gastrointestinal Oncology® (SOGO®)
05/06/23 8:00 AM – 5:00 PM EDT
Expert Illustrations & Commentaries™: Targeting FGFR2b Overexpression in Advanced Gastric and GEJ Cancers
Community Practice Connections™: Analyzing the Evolving Role of Liquid Biopsies Across Cancer Care
Clinical Vignettes™: Testing and Treatment Strategies in Cholangiocarcinoma
Advances In™: The Role of NRG1 Fusions Across Tumor Types
Expert Illustrations & Commentaries™: The Role of B7-H3 Across Tumor Types and How It Could Impact Your Practice in the Future
Community Practice Connections™: 7th Annual School of Gastrointestinal Oncology®
Addressing Racial and Ethnic Disparities in Breast Cancer Care: Improving Outcomes Across the Spectrum of Diagnosis, Trial Access, and Patient Care
ASCO GI: Immunotherapies Boost Survival in Pancreatic CancerJanuary 23rd 2014
The combination of two anticancer vaccines demonstrated improved survival compared to a single vaccine in patients with advanced pancreatic cancer, a particularly difficult to treat tumor type with few therapy options.
Completion of Adjuvant Chemotherapy After Pancreatic Resection Linked With Improved SurvivalJanuary 17th 2014
Completion of 6 cycles of adjuvant chemotherapy, rather than time of initiation, was an independent prognostic factor after resection of pancreatic adenocarcinoma, according to results taken from the phase III European Study Group for Pancreatic Cancer-3.
The War on Pancreatic Cancer: We Are Not There YetJanuary 15th 2014
After 2 decades of disappointing phase III trials and years of single-agent gemcitabine therapy, the pancreatic cancer community is relieved to expand the front-line armamentarium in patients with mPAC. Here we evaluate the current landscape and ask some provocative questions about response rate, dosing, and predictive markers.
Treatment of Metastatic Pancreatic Adenocarcinoma: New Options and Promising StrategiesJanuary 15th 2014
All improvements in outcomes for patients with metastatic pancreatic adenocarcinoma have occurred with the use of cytotoxic agents, which will probably remain the mainstay of treatment for advanced pancreatic adenocarcinoma.
Treatment of Metastatic Pancreatic Adenocarcinoma: A ReviewJanuary 15th 2014
Gemcitabine monotherapy has been the standard of care for patients with metastatic pancreatic cancer for several decades. Despite recent advances in various chemotherapeutic regimens and in the development of targeted therapies, metastatic pancreatic cancer remains highly resistant to chemotherapy.
Expanding Options for Pancreatic Cancer...So Where Do We Go From Here?January 15th 2014
In light of two recent positive clinical trials for advanced pancreatic cancer, we are currently facing an interesting situation that those of us who treat this disease have not had to deal with previously: what to do with this expanding array of choices?
Pancreatic Cancer Death Rates Changing Along Racial LinesDecember 13th 2013
Trends in pancreatic mortality have gone in opposite directions for blacks and whites during the last few decades, a pattern which cannot be explained by known risk factors, according to researchers from the American Cancer Society.
Prolonged Pre-Op Chemo Improved Survival in Pancreatic CancerDecember 13th 2013
Researchers at Kaiser Permanente were able to achieve complete histopathologic response in more than 40% of initially unresectable patients with pancreatic adenocarcinoma who underwent prolonged preoperative chemotherapy and were subsequently able to undergo surgical resection.
BMI Linked to Poor Pancreatic Cancer SurvivalNovember 5th 2013
Patients with a high body mass index prior to being diagnosed with pancreatic cancer had reduced survival from the disease and were more likely to present with late-stage cancer, according to the results of a recently published study.
A Large Cystic Pancreatic Mass in a 45-Year-Old FemaleJuly 15th 2013
The patient is an otherwise healthy 45-year-old female who presented to her primary care physician with 6 weeks of increasing left upper quadrant abdominal pain with radiation to the back. She underwent an abdominal ultrasound, which revealed a large cystic abdominal mass.
"Missing the Target" in Urothelial CancerMarch 16th 2013
Advanced urothelial cancer remains, along with pancreatic cancer, one of the last solid tumors for which essentially no progress has been made for 25 years. It’s time to think out of the box, and to develop novel and creative ways of overcoming the real, but not insurmountable, logistical challenges to carrying out the needed clinical trials.
Keys to Supportive Care in Pancreatic Cancer: Early Palliative Care, Improved CommunicationMarch 15th 2013
Optimal supportive care for patients with pancreatic cancer is essential. Putting these interventions into practice requires that oncologists and oncology teams incorporate innovations at both the individual and the system level.
The Challenge of Palliating Pancreatic CancerMarch 15th 2013
FDA approval of palliative chemotherapy is largely based on disease-free and overall survival, quality of life, and symptom reduction; the latter should be routinely measured by the treating oncologist. Physician assessments of symptoms underreport symptom severity compared to patient-reported symptom assessments.